REMIBRUTINIB SHOWED SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE THROUGH WEEK 52 IN CHRONIC INDUCIBLE URTICARIA

Annals of Allergy, Asthma & Immunology · Elsevier

Аннотация

Publication date: November 2026 Source: Annals of Allergy, Asthma & Immunology, Volume 137, Issue 5, Supplement 2 Author(s): A. Giménez-Arnau, L. Ensina, S. Ferrucci, L. Finklea, A. Fukunaga, K. Hayama, M. Hide, J. Kern, M. Labrador-Horrillo, P. Li, J. Reed, G. Mosnaim, H. Rockmann, S. Saini, P. Staubach, S. Volc, J. Xu, B. Yang, A. Burciu, L. Chen

Читать у издателя →

Похожие статьи